Bayer AG Stock Rises as New Drugs Propel Revenue Increases

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bayer AG (BAYN) stock rose to a record as stronger-than-predicted demand for new drugs outweighed a drop at plastics revenue that the German manufacturer said makes its full-year sales forecast “ambitious.” Revenue from products including the Xarelto blood thinner and Eylea eye medicine “are progressing considerably better than expected,” Leverkusen-based Bayer said in a statement today. The company raised its forecast for sales from new drugs to 1.4 billion euros ($1.9 billion euros) from a previous estimate of 1 billion euros.

Help employers find you! Check out all the jobs and post your resume.

Back to news